Physician profile
Adam D Johnson
NPI 1598002677
$1,439.30
in general payments reported to CMS, 2019-2025
28 companies · $217 in 2025
The $217 reported for 2025 was more than what 77% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.96 · 2022: $358 · 2023: $297 · 2024: $526 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $403.21 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $137.99 | 2022-2024 | Gardasil 9, Rotateq, M-M-R II |
| Sanofi Pasteur INC. | $108.36 | 2021-2024 | |
| Corium, LLC | $85.39 | 2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $81.11 | 2022-2023 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $65.98 | 2023-2025 | |
| Pfizer INC. | $54.91 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $40.64 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $37.81 | 2024-2025 | Doc Band |
| Sobi, INC | $36.37 | 2022-2023 | |
| Inspire Medical Systems, INC. | $35.85 | 2025 | Inspire |
| Abbvie INC. | $32.39 | 2022 | |
| Amgen INC. | $30.66 | 2023-2024 | Repatha, Otezla |
| Seqirus USA INC | $30.49 | 2022 | |
| Tris Pharma INC | $30.11 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.70 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.27 | 2022 | |
| Kaleo, INC. | $21.87 | 2023 | Auvi-Q |
| Neurocrine Biosciences, INC. | $19.88 | 2024 | Ingrezza |
| Lilly USA, LLC | $16.93 | 2023 | Baqsimi, Emgality, Jardiance |
| Daiichi Sankyo INC. | $16.29 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.41 | 2022 | |
| Neurelis, INC. | $15.37 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.21 | 2025 | Alvesco |
| Ironshore Pharmaceuticals INC. | $15.13 | 2024 | |
| Lucid Diagnostics INC. | $14.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.